Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sustained-release tablet containing isradipine

An isradipine and gentle technology, which is applied in the field of sustained-release tablets containing isradipine and its preparation to achieve the effects of maintaining blood drug concentration, lasting drug effect and good reproducibility

Inactive Publication Date: 2014-12-17
SUZHOU UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, the sustained-release preparations of isradipine marketed abroad are sustained-release capsules (2.5mg, 5mg), and there are no related raw materials and preparations on the market in China.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained-release tablet containing isradipine
  • Sustained-release tablet containing isradipine
  • Sustained-release tablet containing isradipine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment one: the preparation of isradipine sustained-release tablet

[0029] Weigh 0.25g isradipine, 1.6g hypromellose K15M, 0.8g hypromellose K100, 2.1g lactose, 2.85g microcrystalline cellulose, mix them uniformly according to the method of equal addition, and mix them with 0.25g 7% hypromellose E6 is a soft material made of binder, granulated with a 24-mesh sieve, dried at 50°C for 2 hours, granulated with a 24-mesh sieve, added 0.1g magnesium stearate, 0.05g silicon dioxide, mixed Evenly, press into tablets.

Embodiment 2

[0030] Embodiment two: preparation of isradipine sustained release tablet

[0031] Weigh 0.25g isradipine, 1.2g hypromellose K15M, 1.2g hypromellose K100, 2.1g lactose, 2.85g microcrystalline cellulose, mix them uniformly according to the method of equal addition, and mix them with 0.25g 7% hypromellose E6 is a soft material made of binder, granulated with a 24-mesh sieve, dried at 50°C for 2 hours, granulated with a 24-mesh sieve, added 0.1g magnesium stearate, 0.05g silicon dioxide, mixed Evenly, press into tablets.

Embodiment 3

[0032] Embodiment three: preparation of isradipine sustained release tablet

[0033] Weigh 0.25g isradipine, 2.0g hypromellose K15M, 0.4g hypromellose K4M, 2.1g lactose, 2.85g microcrystalline cellulose, mix uniformly according to the method of equal addition, and mix with 0.25g 7% hypromellose E6 is a soft material made of binder, granulated with a 24-mesh sieve, dried at 50°C for 2 hours, granulated with a 24-mesh sieve, added 0.1g magnesium stearate, 0.05g silicon dioxide, mixed Evenly, press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a sustained-release tablet containing isradipine. The sustained-release tablet containing the isradipine is mainly prepared from the following raw materials in percentage by mass: 1-10% of isradipine, 20-60% of a framework material, 30-70% of a filler, 2-5% of an adhesive and 0.5-3% of a lubricant. The sustained-release tablet containing the isradipine can be used for treating hypertension. The sustained-release tablet containing the isradipine has the effects of sustained release of medicines, lasting medicine effect and stable blood concentration, has the advantages of reducing medicine administration times, improving medication compliance of patients, reducing adverse effects and improving the safety of medicine administration, and is more suitable for the patients; meanwhile, a preparation method of the sustained-release tablet containing the isradipine is simple in process and favorable for industrial mass production.

Description

technical field [0001] The invention relates to a pharmaceutical preparation and a preparation method thereof, in particular to a sustained-release tablet containing isradipine and a preparation method thereof. Background technique [0002] Hypertension refers to systolic blood pressure > 140 mmHg and / or diastolic blood pressure > 90 mm Hg, based on the average value of 2 or more repeated blood pressure measurements on different days in a resting, non-drug state, and excluding subsequent blood pressure. clinical syndrome of predisposing factors. Hypertension is one of the common cardiovascular diseases, and controlling hypertension is the key to reducing cardiovascular and cerebrovascular events. The incidence of hypertension in my country is increasing year by year, which seriously threatens the health of our people. [0003] Isradipine is a new type of dihydropyridine calcium channel blocker, developed by the Swiss company Sandoz, and first introduced to the market...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/38A61P9/12A61K31/4439A61K9/22
Inventor 曹青日朱晓音崔京浩
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products